TCI Wealth Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

TCI Wealth Advisors’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-119	Closed	-$3.48K	–	2664
2022 Q4	$3.48K	Sell	119 -18	-13%	-$572	﹤0.01%	1770
2022 Q3	$4K	Buy	137 +39	+40%	+$1.43K	﹤0.01%	1707
2022 Q2	$4K	Buy	+98	New	+$4.5K	﹤0.01%	1731
2018 Q4	–	Sell	-14	Closed	-$1K	–	1702
2018 Q3	$1K	Hold	14	–	–	﹤0.01%	1372
2018 Q2	$1K	Hold	14	–	–	﹤0.01%	1412
2018 Q1	$1K	Hold	14	–	–	﹤0.01%	1260
2017 Q4	$1K	Hold	14	–	–	﹤0.01%	1297
2017 Q3	$1K	Hold	14	–	–	﹤0.01%	1229
2017 Q2	$1K	Hold	14	–	–	﹤0.01%	1251
2017 Q1	$1K	Hold	14	–	–	﹤0.01%	1198
2016 Q4	$1K	Hold	14	–	–	﹤0.01%	1264
2016 Q3	$1K	Hold	14	–	–	﹤0.01%	1252
2016 Q2	$1K	Buy	+14	New	+$583	﹤0.01%	1185

Other funds holding EGRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

TCI Wealth Advisors's EGRX Position: Q1 2023 in Review

TCI Wealth Advisors sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2023, closing a stake of 119 shares — an estimated $3.48K sold.

TCI Wealth Advisors first reported a position in EGRX in Q2 2016 and held it in 13 quarters. The position peaked at $4K in Q3 2022. 153 funds tracked by Wall St. Rank hold EGRX as of Q1 2023.

TCI Wealth Advisors reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
TCI Wealth Advisors sold 119 Eagle Pharmaceuticals, Inc. shares in Q1 2023, an estimated $3.48K.
TCI Wealth Advisors first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2016 and held it in 13 quarters.
TCI Wealth Advisors's Eagle Pharmaceuticals, Inc. position peaked at $4K in Q3 2022.
153 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2023.

Based on TCI Wealth Advisors's 13F filing for Q1 2023, filed 3 May 2023.